Evidence map›Paper›PMID 26277551›Full record

ArticleInternational journal of cardiology2015

Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

S M Keating, X Deng, F Fernandes, E Cunha-Neto, A L Ribeiro, B Adesina, A I Beyer, P Contestable, B Custer, M P Busch and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. A SpecificFrontiers in immunology · 2020
    Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Persistent biofluid small molecule alterations induced bybioRxiv : the preprint server for biology · 2023
    Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

S M KeatingBlood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
X DengBlood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
F FernandesHeart Institute (InCor) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
E Cunha-NetoHospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Minas Gerais, Brazil; Heart Institute (InCor) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, São Paulo, SP 06504-000, Brazil.
A L RibeiroHospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
B AdesinaBlood Systems Research Institute, San Francisco, CA, United States.
A I BeyerBlood Systems Research Institute, San Francisco, CA, United States.
P ContestableOrtho Clinical Diagnostics, Rochester, NY, United States.
B CusterBlood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
M P BuschBlood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States. Electronic address: mbusch@bloodsystems.org.
E C SabinoDepartment of Infectious Disease and Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component
Blood Systems Research Institute · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital das Clínicas da Universidade Federal de Minas Gerais · BROrtho Clinical Diagnostics (United States) · USUniversidade de São Paulo · BR

Funding

Sao Paulo-Minas Gerais Tropical Medicine Research Center for Chagas Disease Biomarker DiscoveryU19AI098461 · NIAID · FUNDACAO FACULDADE DE MEDICINA · PI RIBEIRO, ANTONIO LUIZ PINHO · 2017 to 2021
$2.1M
Sao Paulo- MInas Gerais Neglected Tropical Disease Research Center for BiomarkerP50AI098461 · NIAID · FUNDACAO FACULDADE DE MEDICINA · PI SABINO, ESTER CERDEIRA · 2012 to 2016
$1.5M
NHLBI NIH HHS HHSN268200417175CNHLBI NIH HHS HHSN268200517181CNIAID NIH HHS P50 AI098461NIAID NIH HHS P50AI098461NIAID NIH HHS U19 AI098461PHS HHS HHSN268200417175C
6 · The paper itself

Abstract

backgroundChagas disease has a long clinically silent period following Trypanosoma cruzi infection and before development of overt clinical pathology; detectable biomarkers of infection and pathogenesis are urgently needed. We tested 22 biomarkers known to be associated with cardiomyopathy to evaluate if a biomarker signature could successfully classify T. cruzi seropositive subjects into clinical Chagas disease stage groups.

methodsThis cross-sectional retrospective case-control study enrolled T. cruzi seropositive blood donors (BD) who were further characterized as having chronic Chagas cardiomyopathy (CC-BD) or not (nonCC-BD) and seronegative (SN) control donors; we also included clinically diagnosed Chagas cardiomyopathy patients (CC-P). All subjects underwent a health history questionnaire, medical examination, electro- and echocardiograms (ECG and Echo) and phlebotomy. Biomarkers were measured on blinded samples by luminex bead array and Ortho VITROS.

resultsA clear biomarker pattern was observed only in more severe cardiac disease; this pattern included significantly elevated levels of inflammatory cytokines IFN-γ, IL-6, IL-10 and TNF-α and soluble cardiovascular disease biomarkers CK-MB, troponin, myoglobin, VCAM and NTproBNP while there were lower levels of MPO, PAI-1, and MCP-1. The markers determined to be the most predictive of disease by ROC curve analysis were NTproBNP and T. cruzi PCR status.

conclusionsAlthough many biomarkers demonstrated increased or decreased concentrations among the clinical forms of Chagas disease, NTproBNP and T. cruzi PCR were the only tests that would independently be of clinical value for disease staging, in concert with ECG, Echo and clinical assessments.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersBlood DonorsCase-Control StudiesChagas CardiomyopathyChemokinesChildChild, PreschoolCross-Sectional StudiesCytokinesFemaleHumansInfantBiomarkersChemokinesCytokinesNatriuretic Peptide, BrainPeptide FragmentsPlasminogen Activator Inhibitor 1pro-brain natriuretic peptide (1-76)SERPINE1 protein, humanCardiomyopathyChemokinesCytokinesInflammationTrypanosoma cruzi (T. cruzi)

Identifiers

PMID26277551
PMCPMC4868386
OpenAlexW1863368805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.